Drug General Information (ID: DDIYPA1RJL)
Drug Name			Dicoumarol		Drug Info		Velpatasvir		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anticoagulants				Antiviral Agents
Structure

Mechanism of Dicoumarol-Velpatasvir Interaction (Severity Level: Moderate)
Antagonize the effect of antithrombotic agents Click to Show/Hide Mechanism Graph
Drug Name		Dicoumarol				Velpatasvir
Mechanism		Vitamin K antagonist				Interference with hepatic synthesis of vitamin K-dependent coagulation factors
Key Mechanism Factor 1
		Factor Name		Antithrombotic agents
		Factor Description		The beneficial effects of antithrombotic agents are reduced, leading to an increased risk of thromboembolism, stroke and/or myocardial infarction.
Mechanism Description		Antagonize the effect of Dicoumarol when combined with Velpatasvir

Recommended Action
Management		The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
3	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.